Skip to Content

Alfonso Quintas-Cardama

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Universidad de Santiago de Compostela, School of Medicine, Santiago de Compostela, La Coruña, Spain, MD, Medicine and Surgery

Postgraduate Training

7/2006-6/2009 Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff, M.D.
7/2005-6/2006 Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Jorge E. Cortes, M.D.
7/2002-6/2005 Clinical Residency, Internal Medicine, Albert Einstein College of Medicine, Bronx, NY, Steven C. Martin, M.D.
4/1997-4/2000 Clinical Fellowship, Hematology, University of Santiago Clinical Hospital, Santiago, Spain
4/1996-3/1997 Clinical Internship, Internal Medicine, University of Santiago Clinical Hospital, Santiago, Spain

Selected Publications

Peer-Reviewed Original Research Articles
1. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109-17, 4/15/2010. e-Pub 2/3/2010. PMID: 20130243.
2. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. J Clin Oncol 27(32):5418-24, 11/10/2009. e-Pub 10/13/2009. PMID: 19826111.
3. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27(28):4760-6, 10/1/2009. e-Pub 8/31/2009. PMID: 19720904.
4. Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6(9):535-43, 9/2009. e-Pub 8/4/2009. PMID: 19652654.
5. Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115(13):2912-21, 7/1/2009. PMID: 19402171.
6. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2):261-3, 7/9/2009. e-Pub 5/4/2009. PMID: 19414863.
7. Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315-21, 6/18/2009. e-Pub 4/15/2009. PMID: 19369233.
8. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113(8):1619-30, 2/19/2009. e-Pub 9/30/2008. PMID: 18827185.

Grant & Contract Support

Title: hnRNP K:a novel biomarker leukemia and regulator of hematopoietic differentiation
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Sean Post, PhD
Duration: 9/1/2013 - 8/31/2018
 
Title: Therapy with the novel CBP/β-catenin inhibitor PRI-724 for the Cure of Patients with Chronic Myeloid Leukemia Carrying Minimal residual Disease while on Therapy with Tyrosine Kinase Inhibitors
Funding Source: Ladies Leukemia League
Role: Principal Investigator
Duration: 6/1/2012 - 5/30/2013
 
Title: CDP: Impact of Alterations in the P53 Pathway on the Outcome of Patients with B-Cell Chronic Lymphocytic Leukemia. Implications for BTK Therapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 5/1/2012 - 4/30/2013

Last updated: 2/6/2013